Sign Out
Active immunisation against hepatitis A, Active immunisation against hepatitis B
Adult: As susp for inj containing inactivated hepatitis A virus 720 ELISA units and recombinant hepatitis B surface antigen 20 mcg per mL: Primary immunisation: 1 mL given at 0, 1, and 6 months for a total of 3 doses. Alternatively, under exceptional circumstances, an accelerated dosing series of 1 mL given at Days 0, 7, and 21, followed by a booster dose 12 months after the initial dose for a total of 4 doses. Doses are administered via IM inj. In patients with thrombocytopenia or bleeding disorders, some preparations may be given via SC inj but immune response may be reduced. Recommendations may vary between individual products or local immunisation guidelines (refer to specific local guidelines).
Child: As susp for inj containing inactivated hepatitis A virus 360 ELISA units and recombinant hepatitis B surface antigen 10 mcg per 0.5 mL: 1-15 years Primary immunisation: 0.5 mL given at 0, 1, and 6 months for a total of 3 doses. As susp for inj containing inactivated hepatitis A virus 720 ELISA units and recombinant hepatitis B surface antigen 20 mcg per mL: 1-15 years Primary immunisation: 1 mL via IM inj given at 0 and between 6-12 months after the initial dose for a total of 2 doses; ≥16 years Same as adult dose. In patients with thrombocytopenia or bleeding disorders, some preparations may be given via SC inj but immune response may be reduced. Recommendations may vary between individual products or local immunisation guidelines (refer to specific local guidelines).
Child: As susp for inj containing inactivated hepatitis A virus 360 ELISA units and recombinant hepatitis B surface antigen 10 mcg per 0.5 mL: 1-15 years Primary immunisation: 0.5 mL given at 0, 1, and 6 months for a total of 3 doses. As susp for inj containing inactivated hepatitis A virus 720 ELISA units and recombinant hepatitis B surface antigen 20 mcg per mL: 1-15 years Primary immunisation: 1 mL via IM inj given at 0 and between 6-12 months after the initial dose for a total of 2 doses; ≥16 years Same as adult dose. In patients with thrombocytopenia or bleeding disorders, some preparations may be given via SC inj but immune response may be reduced. Recommendations may vary between individual products or local immunisation guidelines (refer to specific local guidelines).
